The April 2026 Department of Justice order, issued under a December 2025 executive directive, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026, and conclude by July 15, governs whether the full rescheduling occurs and directly shapes trader assessments of timelines. The partial action has already altered federal controls for qualifying medical markets, yet complete reclassification requires completing the formal rulemaking process. Traders monitor hearing outcomes, any subsequent final rule publication, and potential litigation as key variables that could accelerate or delay full Schedule III placement.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$764,577 Vol.
31 mar 2026
30 giugno
2%
31 dicembre
27%
$764,577 Vol.
30 giugno
$340,717 Vol.
2%
31 dicembre
$158,977 Vol.
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under a December 2025 executive directive, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026, and conclude by July 15, governs whether the full rescheduling occurs and directly shapes trader assessments of timelines. The partial action has already altered federal controls for qualifying medical markets, yet complete reclassification requires completing the formal rulemaking process. Traders monitor hearing outcomes, any subsequent final rule publication, and potential litigation as key variables that could accelerate or delay full Schedule III placement.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Feb 7, 2026, 5:04 PM ET
Volume
$764,577Data di fine
31 mar 2026Mercato aperto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The April 2026 Department of Justice order, issued under a December 2025 executive directive, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026, and conclude by July 15, governs whether the full rescheduling occurs and directly shapes trader assessments of timelines. The partial action has already altered federal controls for qualifying medical markets, yet complete reclassification requires completing the formal rulemaking process. Traders monitor hearing outcomes, any subsequent final rule publication, and potential litigation as key variables that could accelerate or delay full Schedule III placement.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$764,577Data di fine
31 mar 2026Mercato aperto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The April 2026 Department of Justice order, issued under a December 2025 executive directive, immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling from Schedule I. That hearing, set to begin June 29, 2026, and conclude by July 15, governs whether the full rescheduling occurs and directly shapes trader assessments of timelines. The partial action has already altered federal controls for qualifying medical markets, yet complete reclassification requires completing the formal rulemaking process. Traders monitor hearing outcomes, any subsequent final rule publication, and potential litigation as key variables that could accelerate or delay full Schedule III placement.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti